VivaVision Biotechnology, Inc.
http://www.vivavisionbio.com/en/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From VivaVision Biotechnology, Inc.
China Biotech Finance Watch: Luzhu Bags $43.5m In Hong Kong IPO
In the private market, eight Chinese biotechs raised a combined $116m in deals backed by venture capital and private equity firms over the past few weeks.
Asia Deal Watch: Astellas Begins 2023 Signing Rare Disease Tie-Ups With Selecta, Twist
Evopoint and Kaken also ring in the new year with multiple deals. Biocytogen licenses antibodies against a specified target derived from its RenMice platform technology to Hansoh Pharma.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Visou Biotechnology
- Weimou Biotechnology Co, Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice